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SUMMARY
1. There is a growing interest in the anti-oxidant characteristics
and use of flavonoids in the management of cardiovascular
diseases. The cardiovascular mechanism of action of these
plant derivatives remains controversial. This study compared the
effects of the flavonoid quercetin with those of the anti-oxidant
vitamin ascorbic acid (vitamin C) on the reactivity of aortic
rings from spontaneously hypertensive rats (SHR).
2. The phenylephrine (PE)-induced contractile and the
endothelium-dependent and independent relaxant responses
of aortic rings from 21 to 22 week old SHR and age-matched
normotensive Wistar (WKY) rats were observed in the presence
of quercetin or ascorbic acid. All the experiments were performed
in the presence of the cyclooxygenase inhibitor, indomethacin
(10 mmol/L).
3. The endothelium-dependent and independent relaxations
to acetylcholine (ACh) and sodium nitroprusside (SNP), respec-
tively, were significantly lesser in the SHR compared to the WKY
tissues whereas the contractile responses to PE were similar
in both tissues. Pretreatment of WKY rings with quercetin or
ascorbic acid had no effect on the responses to ACh or PE. In
the SHR tissues, however, quercetin or ascorbic acid significantly
improved the relaxation responses to ACh and reduced the
contractions to PE with greater potency for quercetin. Both
compounds lacked any effects on the responses to SNP in either
aortic ring types. Nw-nitro-L-arginine methyl ester (L-NAME,
10 mmol/L) significantly attenuated the vasodepressor effects of
quercetin and ascorbic acid, raising the responses to PE to a level
similar to that observed in the control SHR tissues. In L-NAME
pretreated aortic rings, quercetin and ascorbic acid inhibited the
contractile responses to PE with the same magnitude in WKY
and SHR tissues.
4. The present results suggest that acute exposure to quercetin
improves endothelium-dependent relaxation and reduces
the contractile responses of hypertensive aortae with a greater
potency than ascorbic acid. This suggests a better vascular
protection with this flavonoid than ascorbic acid in the SHR
model of hypertension and possibly in human cardiovascular
diseases.
Key words: anti-oxidants, ascorbic acid, endothelium, hyper-
tension, nitric oxide, quercetin, SHR.
INTRODUCTION
Hypertension is one of the common risk factors for the development
of coronary artery disease (CAD). It is associated with oxidative
stress and increased free radicals, which may contribute to the develop-
ment of complications such as the reduction in endothelium-dependent
relaxation of vascular smooth muscles.1,2 Superoxide anion is an
important member of the free radical family and together with its
derivatives, it counteracts the relaxing activity of endothelium-derived
nitric oxide (EDNO) and prostacyclin (PGI2).
3,4 Prevailing evidence
from both human and animal studies indicate that dietary anti-oxidants
can prevent the development of the vascular complications associated
with hypertension.5,6
Recent evidence suggests flavonoids, a group of polyphenolic
compounds found in human diet, as potential candidates for the
prevention of morbidity and mortality due to CAD.7,8 The vascular
beneficial effects of flavonoids are attributed primarily to their
interactions with the EDNO system.9 Flavonoids have been shown
to improve the bioavailability of EDNO by directly interacting with
superoxide anions and other free radicals which are known to destroy
EDNO.10,11 In addition to enhancing EDNO bioavailability, flavonoids
are also reported to produce relaxant effects in various vascular pre-
parations by enhancing EDNO production either by stimulating
the activity or by enhancing the expression of endothelial nitric oxide
synthase (eNOS).12–14 Quercetin is the most commonly found flavonoid
in the human diet and has been shown to possess potent vasodilator
and anti-oxidant activities.13,15,16 Indeed, chronic oral treatment
with quercetin has been reported to protect against impaired vascular
endothelial function in various models of experimental hypertension.17,18
Unfortunately, there was only one study looking at the acute effects
of quercetin on blunted endothelium-dependent relaxations in
isolated hypertensive arteries.19 Furthermore, to our knowledge, no
studies have compared the endothelial protective effects of flavonoids
with those of dietary anti-oxidant vitamins. Therefore, the present study
examined the direct effects of quercetin on endothelium-dependent
relaxation induced by acetylcholine (ACh) in isolated aortic rings
from spontaneously hypertensive rats (SHR). The effects of quercetin
on the responsiveness of SHR aortic rings to endothelium-independent
vasodilator sodium nitroprusside (SNP) or to a1-adrenergic receptor
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agonist phenylephrine (PE) were also examined. The effects of quercetin
were compared with those of l-ascorbic acid (vitamin C).
MATERIALS AND METHODS
Drugs and chemicals
l-ascorbic acid, quercetin, phenylephrine-HCl, acetylcholine chloride,
indomethacin and Nw-nitro-L-arginine methyl ester were purchased from
Sigma Chemicals (St. Louis, MO, USA). Sodium nitroprusside and Kreb’s salts
were purchased from BDH Limited (Poole, England). Except for indomethacin,
quercetin and ascorbic acid all the other drug solutions were prepared freshly
on the day of experiment by dissolving weighed amount of respective drugs
in distilled water. Indomethacin was prepared in stock (10 mmol/L) in 0.5%
w/v sodium carbonate and diluted with distilled water. Quercetin and
ascorbic acid were each prepared as stock solution, 10 mmol/L, with
dimethyl sulfoxide (DMSO). The final concentrations were prepared by serial
dilutions with distilled water; DMSO concentration was adjusted to less than
0.05% v/v.
Animals
The experiments were performed on male spontaneously hypertensive rats
(SHR) and their sex- and age-matched normotensive Wistar-Kyoto (WKY)
rats weighing 250–300 g (21–22 weeks old). The animals were housed in
plastic cages (four in each) with free access to standard rat chow (Gold Coin
Sdn. Bhd. Malaysia) and tap water. All the experimental procedures were
subjected to The University of Malaya Animal Experimentation Ethics Com-
mittee approval.
Vascular ring preparation
The animals were anaesthetized with a single intraperitoneal dose of pento-
barbitone sodium (60 mg/kg bodyweight). Thereafter, the descending tho-
racic aorta was excised through a ventral incision and was cleaned of fat and
connective tissues; care was taken not to dislodge the vascular endothelium.
The aorta was sectioned into small rings (3–5 mm in width), which were then
mounted in a jacketed organ bath containing 5 mL of normal Kreb’s physio-
logical salt solution (KPSS) of the following composition (mmol/L): NaCl
118.2, KCl 4.7, CaCl2.2H2O 2.5, KH2PO4 1.2, MgCl2 1.2, glucose 11.7,
NaHCO3 25.0, and EDTA 0,026. The bath solution was maintained at 37∞C
and oxygenated continuously with a mixture of 95% oxygen and 5% carbon
dioxide. The rings were attached to isometric force-displacement transducers
(Grass Instrument Co. Quincy, MA) and the transducer output was amplified
and recorded continuously using the Mac Laboratory recording system (AD
Instruments, Australia) connected to a portable computer display monitor.
The rings were equilibrated for 45 min under 1 g resting tension. During this
period of stabilization the bath solution was replaced every 15 min. Follow-
ing the equilibration, the contractile responses of aortic rings were tested for
viability by the addition of KPSS containing 10% (w/v) KCl (high K+). The
rings were contracted for 5 min every 10 min until two consecutive equal
contractions were attained – evidence of tissue stability. Following washout
of the responses to high K+, the rings were incubated with indomethacin
(10 mmol/L) for 10 min and further experimental procedures were carried
out in its presence. The concentration of quercetin was selected based on
previous investigations from this lab which showed that at this concentration
quercetin produced more than 50% relaxation in high K+ and PE precon-
tracted aortic rings from WKY rats.13
Pharmacological studies
The responses of aortic rings from SHR and WKY rats to endothelium-
dependent and -independent relaxants ACh and SNP, respectively, were
examined under submaximal PE (10 mmol/L)-induced contraction. The
responses of the aortic rings to cumulative concentrations of ACh (from 10-10
to 10-5 mol) or SNP (from 10-11 to 10-6 mol) were recorded at intervals of
3 min in separate tissues incubated in KPSS to which was added vehicle,
quercetin (10 mmol/L) or ascorbic acid (10 mmol/L) 20 min prior to PE
stimulation and throughout the experiment.
In another set of experiments, aortic rings from SHR or WKY rats were
incubated for 20 min in KPSS to which was added vehicle, quercetin
(10 mmol/L) or ascorbic acid (10 mmol/L) and the contractile responses to
cumulative concentrations of PE (from 10-10 to 10-5 mol) were recorded at
intervals of 3 min. The protocol was repeated with a separate set of aortic
rings which were exposed, throughout the experiment, to the eNOS inhibitor
w-nitro-L-arginine methyl ester (l-NAME, 10 mmol/L).
Data presentation and statistical analysis
The concentrations given in the text or in figures represent final bath
concentrations of respective agonists. The relaxant responses to ACh and
SNP were calculated as percentage reduction of the PE (1 mmol/L) -induced
maximal contraction, while the contractile responses to PE were recorded
as percentage of the maximum contractile response to high K+. With the
aid of a computer software (Prism 2.0, Graph Pad software, USA) the
values were plotted to obtain a best-fit dose–response curve with the maximal
response (Rmax, maximum agonist-induced response) and pEC50 (negative
logarithm of 50% effective concentration) values determined. The observed
responses were analysed for statistical significance using Student’s t-test
(Microsoft Excel, Microsoft Corp., USA) for unpaired observations and
the one way analysis of variance (anova) for multiple value comparison
(Prism 2.0, GraphPad Software, USA). A value of P < 0.05 was considered
statistically significant.
RESULTS
ACh- and SNP-induced vasodilatations
Figure 1 summarizes the data on the relaxant effects of ACh in the
different experimental conditions. The cumulative addition of ACh
led to a concentration-dependent relaxation of PE-contracted WKY
and SHR aortae (Fig. 1). Control SHR aortic rings demonstrated
marked reduction in their response to ACh compared to rings from
control WKY rats (Fig. 1/ Table 1). In WKY aortic rings incubated
either with quercetin or ascorbic acid their peak relaxation responses
to ACh remain comparable to control WKY aortae (Table 1). In SHR
aortic rings incubated with quercetin (10 mmol/L) the peak relaxant
effect to ACh was markedly improved compared to control SHR aor-
tic rings (Table 1). Indeed, the relaxations to ACh were restored to
a similar extent as in control WKY aortae (Fig. 1). Similarly, in SHR
aortic rings incubated with l-ascorbic acid the maximal response to
ACh was significantly improved (Fig. 1/Table 1).
Figure 2 illustrates the relaxant responses to endothelium-
independent vasodilator, SNP, in all experimental groups. The maximal
relaxant response to SNP was significantly lesser in control SHR
aortic rings compared with aortic rings attained from WKY rats (Fig. 2/
Table 1). In addition, irrespective of the quercetin or ascorbic acid
pretreatment, the vasodilatation responses to SNP remain unchanged
in both WKY and SHR aortae compared to their respective controls
(Fig. 2/Table 1).
Contractile responses to PE stimulation
The exposure of vehicle-treated (control) WKY and SHR aortic
rings to PE led to a concentration-dependent rise in tension in both
experimental groups (Fig. 3). There were no significant differences
in the responses to PE between the WKY and SHR aortic rings










Flavonoids, endothelium, and hypertension 347
© 2006 Blackwell Publishing Asia Pty Ltd
Fig. 1 Relaxant responses to endothelium-
dependent vasodilator acetylcholine (ACh)
in vehicle (control, ), quercetin () or
ascorbic acid () incubated aortic rings
from WKY (A) and SHR (B) rats. Symbols
represent mean±SEM of 6 or 7 experiments.
*P < 0.05 control WKY versus control
SHR aortic rings, #P < 0.05 control SHR
versus quercetin or ascorbic acid incubated
SHR aortic rings.
Table 1 Responses of normal (WKY) and hypertensive (SHR) aortic rings to endothelium-dependent vasodilator acetylcholine (ACh), to endothelium-
independent vasodilator sodium nitroprusside (SNP) and to a1-adrenergic receptor agonist phenylephrine (PE) under different experimental conditions. Values
























WKY + vehicle 127.6 ± 6.9 7.07 ± 0.11 86.9 ± 4.8 7.75 ± 0.21 104.0 ± 1.0 7.68 ± 0.17
WKY + quercetin 136.6 ± 5.5 6.84 ± 0.09 91.0 ± 4.26 7.70 ± 0.1 104.8 ± 1.75 7.98 ± 0.11
WKY + ascorbic acid 119.8 ± 8.6 7.13 ± 0.12 89.6 ± 6.1 7.55 ± 0.15 101.9 ± 4.4 8.01 ± 0.13
WKY + l-NAME 185.41 ± 7.9* 9.02 ± 1.53 ND ND ND ND
WKY + l-NAME + quercetin 151.3 ± 6.7§ 8.68 ± 1.60 ND ND ND ND
WKY + l-NAME + ascorbic acid 158.6 ± 8.01§ 7.63 ± 0.13 ND ND ND ND
SHR + vehicle 118.5 ± 4.5 7.29 ± 0.11 72.8 ± 1.9* 7.27 ± 0.09 96.7 ± 1.9* 7.77 ± 0.08
SHR + quercetin 71.2 ± 11.0†,‡ 7.18 ± 0.30 91.1 ± 4.1† 7.61 ± 0.08 98.9 ± 2.5 7.92 ± 0.12
SHR + ascorbic acid 96.65 ± 6.6† 7.03 ± 0.12 89.1 ± 2.8† 7.19 ± 0.09 98.4 ± 1.4 8.10 ± 0.08
SHR + l-NAME 147.3 ± 4.5† 7.42 ± 0.22 ND ND ND ND
SHR + l-NAME + quercetin 119.9 ± 9.7§ 7.14 ± 0.34 ND ND ND ND
SHR + l-NAME + ascorbic acid 126.0 ± 4.8§ 7.11 ± 0.11 ND ND ND ND
ND = not determined, *P < 0.05 versus control WKY aortic rings, †P < 0.05 versus control SHR aortic rings, ‡P < 0.05 versus ascorbic acid incubated
SHR aortic rings, §P < 0.05 versus corresponding l-NAME pretreated aortic rings.
Fig. 2 Relaxant responses to endothelium-
independent vasodilator sodium nitroprusside
(SNP) in vehicle (control, ), quercetin
() or ascorbic acid () incubated aortic
rings from WKY (A) and SHR (B) rats.
Symbols represent mean±SEM of 6 or 7
experiments. *P < 0.05 control WKY versus
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or ascorbic acid the peak contractile response to PE remained
comparable (P > 0.05) to the control WKY aortae (Table 1/Fig. 3).
In contrast, in SHR aortic rings incubated either with quercetin or
ascorbic acid the peak contractile response to PE was significantly
lesser than that of the control SHR aortic rings (Fig. 3/Table 1). In
addition, compared with ascorbic acid- incubated SHR aortic rings,
the maximal contractile response to PE was significantly lesser in
the quercetin- incubated SHR tissues (Table 1).
In the presence of l-NAME (10 mmol/L) the maximum contractile
response of WKY and SHR aortic rings to PE was significantly enhanced
(Table 1). This enhanced contraction was however, partially reversed
by quercetin and ascorbic acid in WKY, but not SHR tissues where
the l-NAME effect was fully reversed (Table 1/ Fig. 4). In addition,
in the presence of l-NAME the peak contractile responses to PE of the
quercetin- or ascorbic acid- treated SHR aortic rings were essentially
similar to that in control SHR aortic rings (Table 1/Fig. 4).
DISCUSSION
Consistent with earlier reports of impaired ACh-induced relaxation
in hypertension,1,2,5,6 the relaxation responses to ACh were significantly
lesser in hypertensive aortae compared to normotensive aortae (Fig. 1).
The incubation of the hypertensive tissues with either quercetin or
ascorbic acid enhanced their relaxation responses to ACh indicating
that ascorbic acid and quercetin promote the EDNO-mediated
relaxant response to ACh in the SHR tissues. Blunted ACh-induced
relaxation in hypertensive arteries have been previously attributed
to overproduction of endothelium-derived constrictor prostanoids
and/or superoxide anions.3,4,20 All experiments in this study were per-
formed in the presence of the cyclooxygenase inhibitor, indometh-
acin, with the view to eliminating the generation of constrictor or
relaxant prostanoids. The blunted relaxations to ACh observed in
hypertensive tissues therefore are probably the result of the detri-
mental effects of superoxide anions and other free radicals on EDNO
and not the result of EDNO-prostanoid cross-talk. It follows that the
enhancement by quercetin or ascorbic acid of the ACh-induced
relaxation in hypertensive tissues is probably due to its superoxide
anion scavenging property as previously reported.10,21 A superoxide
scavenging role for quercetin or ascorbic acid is also consistent with
its inhibition of PE-induced contraction of hypertensive tissues (Fig. 3).
This inhibition, as argued above, cannot be attributed to a cyclo-
oxygenase product. We suggest that by scavenging superoxide anions
(anti-oxidant effect) quercetin or ascorbic acid enhanced the
bioavailability of EDNO, thus, enhancing the relaxant responses of
hypertensive tissues to ACh (Fig. 1) or inhibiting their contractile
responses to PE (Fig. 3). The inhibitory effects of quercetin or
ascorbic acid on PE-induced contraction of hypertensive aortas
(Fig. 3) were significantly prevented in the absence of EDNO
Fig. 3 Contractile responses to PE in
vehicle (control, ), quercetin () or
ascorbic acid () pretreated aortic rings
from WKY (A) and SHR (B) rats. Symbols
represent mean±SEM of 6 or 7 experiments.
*P < 0.05 control SHR versus quercetin
or ascorbic acid pretreated SHR aortic
rings, #P < 0.05 quercetin versus ascorbic
acid pretreated SHR aortic rings.
Fig. 4 PE-induced contractions of WKY
(A) and SHR (B) aortic rings pretreated
with vehicle (Control, ), l-NAME (),
l-NAME with quercetin () or l-NAME
with ascorbic acid (). Symbols represent
mean±SEM of 6 or 7 experiments. *P < 0.05
control versus L-NAME pretreated aortic
rings, #P < 0.05 l-NAME versus L-NAME
with quercetin or L-NAME with ascorbic
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synthesis (i.e. presence of l-NAME- Fig. 4), again suggesting that
the effects of quercetin and ascorbic acid were mediated, at least in
part, by improved EDNO.
Interestingly, the (ACh) relaxation-enhancing and (PE) contraction-
inhibiting effects of quercetin and ascorbic acid on hypertensive
(SHR) tissues were not observed with the normal (WKY) tissues.
It is well known that normotensive WKY tissues produce little or
no free radicals.4,21 We therefore postulate that the failure to elicit
effect with quercetin or ascorbic acid in the normal tissues is a reflec-
tion of the absence of free radicals in those tissues. The direct meas-
urement of free radicals which we were unable to perform in this
study will be useful in clarifying these assumptions.
Incubation of either normal or hypertensive tissues with quercetin
or ascorbic acid did not enhance the relaxant responses to the
endothelium-independent vasodilator, SNP. Perhaps by enhancing
NO bioavailability through its NO donor effect, SNP provided full
NO-mediated relaxation, thus ‘usurping’ the action of quercetin and
ascorbic acid. This view is consistent with reports by earlier workers
that flavonoids accumulate on the surface between the endothelial
and vascular smooth muscle cells10,22 and exert beneficial vascular
effects by either enhancing EDNO production or inhibiting its
destruction by free radicals; in either case improving EDNO bio-
availability.10–14
Defects in the nitric oxide signal transduction pathways including
the down regulation of guanylate cyclase (sGC) followed by
impaired cGMP production are the other possible mechanisms
implicated in the impaired responses of hypertensive vessels.23,24
This view is supported by the observed reduction in SNP/NO/sGC/
cGMP-mediated relaxation responses in hypertensive compared to
the normotensive aortae (Table 1/Fig. 2), given that in both cases NO
bioavailability has been assured by the NO donor- SNP. Treatment
of the hypertensive vessels with quercetin or ascorbic acid did not
enhance the relaxant response to SNP. This is an indirect evidence
that the beneficial (relaxant) effect of quercetin or ascorbic acid is
not through the enhancement of the downstream (NO/sGC/cGMP)
NO signal transduction pathway, but rather by improving the
upstream EDNO bioavailability as described above.
Quercetin has been shown in vitro to possess higher superoxide
scavenging and anti-oxidant activities than ascorbic acid.15,25 Con-
sistent with these reports, quercetin in the present study elicited a
significantly higher reduction in the constrictor responses to PE than
did ascorbic acid in hypertensive tissues (Fig. 3). In addition, quer-
cetin also elicited a greater enhancement of ACh-induced relaxation
of hypertensive tissues (Fig. 1).
In normotensive (WKY) tissues, treatment with l-NAME caused
significant increases in the contractile responses to PE (Fig. 4) which
was partially reversed by incubation of the tissues in either quercetin
or ascorbic acid. Granted that the l-NAME-induced increased
contraction is a result of abolition of EDNO production, it could be
argued that the partial reversal of the l-NAME effect is an indication
that quercetin and ascorbic acid probably inhibit PE-induced
contraction by some l-NAME-insensitive process. This, as previously
reported for some flavonoids, may be an l-NAME insensitive NO
pool or endothelium-derived hyperpolarising factor.26,27 In the
SHR tissues both quercetin and ascorbic acid reversed the l-NAME
increased contraction to normal level. This result is consistent with
the view that the anti-oxidants (ascorbic acid or quercetin) inhibit PE-
induced contraction in the hypertensive tissues through enhancing an
l-NAME sensitive NO pool. The complete reversal of the contraction
in SHR as against WKY tissues suggests that the l-NAME insensitive
mechanisms observed in the WKY may be down-regulated or absent
in the SHR tissues.
In conclusion, the results showed that acute exposure to quercetin
improves endothelium-dependent vascular relaxation and reduces
a1-adrenergic receptor mediated contractions of isolated hyperten-
sive aortae, with greater potency than ascorbic acid. This suggests
a better vascular protective effect with this flavonoid than with
ascorbic acid in SHR model of hypertension and possibly in human
cardiovascular diseases. These effects of quercetin probably results
from its endothelial nitric oxide protective effects although participa-
tion of other mechanism(s) can not be ruled out.
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